BridgeBio Pharma Inc

NASDAQ:BBIO  
43.99
+1.16 (+2.71%)
4:20:00 PM EDT: $43.99 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)8.58B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$96.22 Million
Adjusted EPS-$0.76
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

BridgeBio Pharma Inc Stock, NASDAQ:BBIO

3160 Porter Drive, Suite 250, Palo Alto, California 94304
United States of America
Phone: +1.650.391.9740
Number of Employees: 730

Description

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.